Movement Disorders

David Evans, MBA, shared his experience from this year’s event and spoke about the progress that’s been made in advocating for patients in the last several years at the AAN's Neurology on the Hill conference.

Robert A. Hauser, MD, MBA, discusses the appearance of OFF episodes throughout progression of Parkinson disease.

Laxman Bahroo, DO, and Rajesh Pahwa, MD, comment on the identification and presentation of OFF episodes in patients with Parkinson disease.

The founder and chief medical officer of Omniscient Neurotechnology provided commentary on expanding the brain map, the use of advanced technology, and the need to familiarize clinicians with connectomics.

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]

The founder and chief medical officer of Omniscient Neurotechnology provided insight on the successes using connectomics, including the FDA approval of Quicktome, a digital brain mapping platform. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuropathic disorders.

If approved, ABBV-951 would become the first subcutaneous delivery of levodopa and carbidopa, the gold standard for symptom management in Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 20, 2022.

The founder and chief medical officer of Omniscient Neurotechnology discussed the idea behind connectomics and how AI revolutionizes large-scale brain data. [WATCH TIME: 4 minutes]

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, define the difference between ON time and OFF episodes for patients with Parkinson disease.

Rajesh Pahwa, MD, reviews the use of levodopa for the management of Parkinson disease symptoms.

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps to justify whether reflex tears are a reliable biomarker for Parkinson disease.

The importance of addressing disorders of the brain cannot be overstated, and doing so will be essential to our generation and generations to come.

The chief executive officer of the Child Neurology Foundation provided insight on her new position at the National Health Institute’s National Advisory Neurological Disorders and Stroke Council. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 13, 2022.

John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the efforts needed to validate tears as a biomarker in patients who don’t present with typical Parkinson disease. [WATCH TIME: 4 minutes]

The chief executive officer of the Child Neurology Foundation discussed how her background in pediatric neurology will be used in a newly appointed NIH council position.

The chief executive officer of the Child Neurology Foundation provided insight on the ongoing efforts to make children with neurological conditions feel inclusive in today’s society. [WATCH TIME: 3 minutes]

The assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute discussed the need to understand the chemical markers that trigger nonmotor symptoms of Parkinson disease. [WATCH TIME: 3 minutes]

The director of the Division of Movement Disorders at the USC Keck School of Medicine provided insight on the next steps in how we can expand on tears as a valuable biomarker for neurodegenerative diseases. [WATCH TIME: 4 minutes]